New! Sign up for our free email newsletter.
Science News
from research organizations

A new tuberculosis vaccine candidate recombinant protein with additional post-translational modifications occurring in Mycobacterium tuberculosis cells

Date:
June 19, 2024
Source:
Niigata University
Summary:
Tuberculosis is a serious health threat, and the efficacy of the BCG vaccine against tuberculosis diminishes in adulthood, making booster vaccines a realistic option. Mycobacterial DNA-binding protein 1 (MDP1), a protein found in Mycobacterium tuberculosis, elicits higher protective IFN-gamma responses in individuals who suppress tuberculosis, thus making it a vaccine candidate.
Share:
FULL STORY

Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide. Additionally, about one-fourth of the world's population carries Mycobacterium tuberculosis (M. tuberculosis) without showing any symptoms, and most of these carriers do not develop the disease.

The current anti-tuberculosis vaccine, BCG, is administered worldwide. However, considering that more than 10 million new tuberculosis cases are reported each year, its effectiveness is deemed insufficient. As a result, the development of vaccines to replace BCG is underway. However, no new vaccine has yet surpassed BCG, which is a highly effective live vaccine. Actually BCG is very effective in preventing tuberculosis in children, creating a booster vaccine to strengthen immunity in adults is considered a promising and realistic option.

In developing tuberculosis vaccines, scientists have studied proteins from M. tuberculosis that trigger the protective immunity against tuberculosis. Especially IFN-gamma produced by T cells is known to be critical for protection against tuberculosis. Thus IFN-gamma responses are marker of vaccine candidate antigens and efficacy. However there's a paradoxical situation where proteins that induce higher IFN-gamma production in tuberculosis patients, who already have developed the disease, rather than in asymptomatic carriers who prevent its onset, are being viewed as potential vaccine candidates. Furthermore, many of vaccine studies ignore the native three-dimensional structure of the proteins and the modification they undergo after being translated in M. tuberculosis.

On the productivity side, vaccine candidate molecules are being made in basic model organisms like Escherichia coli. However, certain molecules undergo specific changes after translation that are unique to the pathogen, such as M. tuberculosis. It's been noted that these modifications might be crucial for mounting effective defenses against actual pathogen attacks.

Mycobacterial DNA-binding protein 1 (MDP1) is a major protein of both BCG and M. tuberculosis (Shaban et al., Sci Rep., 2024) with extensive post-translational modifications (Yoshida et al., BBRC., 2023). Recent studies show that IFN-gamma responses to MDP1 are higher in individuals who suppress tuberculosis progression compared to tuberculosis patients, making MDP1 a new vaccine candidate (Yasuda et al., Front Immunol., 2024). To evaluate MDP1 for a tuberculosis booster vaccine, Ozeki et al. produced recombinant MDP1 and tested its ability to induce IFN-gamma using blood from BCG-vaccinated adults.

Ozeki et al., expressed MDP1 in two different hosts: M. smegmatis, a non-pathogenic, fast-growing mycobacteria, and E. coli. Importantly, the MDP1 expressed in M. smegmatis (mMDP1) showed significant post-translational modifications, closely resembling the native MDP1 found in M. tuberculosis, while the one expressed in E. coli (eMDP1) did not.

When they cultured both variants of MDP1 with peripheral blood from adults vaccinated with BCG, they observed that mMDP1 triggered notably higher levels of IFN-gamma production compared to eMDP1. This implies that the immune system of BCG-vaccinated adults can recognize MDP1 with post-translational modifications.

Importantly, mMDP1 demonstrated a superior capacity for IFN-gamma production compared to other vaccine candidate antigens, such as Antigen 85 complex, which is currently in development. When utilizing protein antigens as vaccines, adjuvants are typically employed to prevent degradation or enhance immunogenicity. We previously reported that MDP1, due to its binding affinity to bacterial DNA, has protected mice from M. tuberculosis infection when co-administered. In this study we also demonstrated that the combination of mMDP1 and G9.1, a novel type of CpG-DNA, elicits a significant level of IFN-gamma from peripheral blood of BCG-vaccinated adults.

The results of this study suggest that combining mMDP1, which displays post-translational modifications, with G9.1 can reinvigorate the waning effect of BCG, indicating its potential as a booster vaccine.


Story Source:

Materials provided by Niigata University. Note: Content may be edited for style and length.


Journal Reference:

  1. Yuriko Ozeki, Akira Yokoyama, Akihito Nishiyama, Yutaka Yoshida, Yukiko Ohara, Tsukasa Mashima, Chikako Tomiyama, Amina K. Shaban, Atsuki Takeishi, Mayuko Osada-Oka, Takehiro Yamaguchi, Yoshitaka Tateishi, Jun-ichi Maeyama, Mariko Hakamata, Hiroshi Moro, Toshiaki Kikuchi, Daisuke Hayashi, Fumiko Suzuki, Toshiko Yamamoto, Sumiko Iho, Masato Katahira, Saburo Yamamoto, Sohkichi Matsumoto. Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals’ blood cells in combination with CpG-DNA. Scientific Reports, 2024; 14 (1) DOI: 10.1038/s41598-024-58836-8

Cite This Page:

Niigata University. "A new tuberculosis vaccine candidate recombinant protein with additional post-translational modifications occurring in Mycobacterium tuberculosis cells." ScienceDaily. ScienceDaily, 19 June 2024. <www.sciencedaily.com/releases/2024/06/240619143640.htm>.
Niigata University. (2024, June 19). A new tuberculosis vaccine candidate recombinant protein with additional post-translational modifications occurring in Mycobacterium tuberculosis cells. ScienceDaily. Retrieved July 22, 2024 from www.sciencedaily.com/releases/2024/06/240619143640.htm
Niigata University. "A new tuberculosis vaccine candidate recombinant protein with additional post-translational modifications occurring in Mycobacterium tuberculosis cells." ScienceDaily. www.sciencedaily.com/releases/2024/06/240619143640.htm (accessed July 22, 2024).

Explore More

from ScienceDaily

RELATED STORIES